One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
AbCellera Biologics logo
AbCellera Biologics ABCL
$ 9.63 -7.85%
report update icon

Quarterly report 2026-Q3
added 11-09-2026

AbCellera Biologics Financial Ratios 2025-2011 | ABCL

Brief overview of AbCellera Biologics's multiples and efficiency

Current figures are compared with the company's own five-year history for 2021–2025.

The valuation comparison uses P/E 16.02x (median 16.02x), EV/EBITDA 10.07x (median 10.07x), P/S 12.8x (median 12.8x). Current valuation broadly matches recent historical reference points; the difference from five-year medians is 0%.

Current earnings relative to valuation equal about 6.2% on the 1/P/E measure. This is a valuation reference, not an expected payout.

Returns on assets and capital are represented by ROE -15.1%, ROA -10.8%, ROCE -16.8%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.

PEG of 0.17x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.

The cash conversion cycle decreased 29 days to 173.4 days, supporting working-capital efficiency.

Overall assessment

AbCellera Biologics's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.

Annual Financial Ratios AbCellera Biologics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-6.6 -5.3 -10.4 16.0 15.7 50.5 - - - - - - - - -

P/S

12.8 29.8 40.2 5.2 6.4 25.7 - - - - - - - - -

EPS

-0.5 -0.6 -0.5 0.6 0.6 0.5 -0.0 - - - - - - - -

EV (Enterprise Value)

1.22 B 1.01 B 1.73 B 2.46 B 2.19 B 5.58 B 13.2 M 9.88 M - - - - - - -

EBITDA per Share

-0.67 -1.03 -0.74 0.86 0.79 0.99 - - - - - - - - -

EV/EBITDA

-6.2 -3.3 -8.1 10.1 9.2 50.3 - - - - - - - - -

PEG

0.17 - - - - 0.01 - - - - - - - - -

P/B

1.0 0.8 1.3 2.1 2.3 7.2 - - - - - - - - -

P/CF

-7.3 -7.9 -34.8 9.2 9.8 264.6 - - - - - - - - -

ROE %

-15.14 -15.42 -12.70 12.85 14.96 14.32 - - - - - - - - -

ROA %

-10.79 -11.97 -9.84 10.29 11.64 11.83 - - - - - - - - -

ROCE %

-16.80 -24.52 -17.33 15.22 17.06 17.30 - - - - - - - - -

Current Ratio

3.5 4.5 4.4 5.0 4.5 5.7 - - - - - - - - -

DSO

173.4 202.4 - - - - - - - - - - - - -

Operating Cycle

173.4 202.4 - - - - - - - - - - - - -

Cash Conversion Cycle

173.4 202.4 - - - - - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios AbCellera Biologics

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.13 -0.18 -0.14 - -0.19 -0.12 -0.15 - -0.17 -0.13 -0.14 - -0.1 -0.11 -0.14 - 0.09 -0.02 0.59 - -0.08 -0.01 0.43 - -0.02 0.03 -0.01 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.15 -0.18 -0.17 - -0.24 -0.15 -0.19 - -0.19 -0.19 -0.17 - -0.18 -0.17 -0.21 - 0.15 -0.01 0.81 - -0.09 -0.01 0.6 - -0.01 - -0.01 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-20.55 -20.16 -18.43 -13.83 -18.57 -15.97 -16.12 -11.66 -14.08 -11.89 -11.89 -8.29 -6.16 -4.30 12.21 15.53 13.29 10.92 23.73 9.76 9.44 12.49 12.48 0.23 -0.32 0.81 -0.25 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-14.47 -14.23 -13.39 -10.08 -13.75 -12.15 -12.45 -9.06 -10.95 -9.27 -9.33 -6.56 -4.84 -3.37 9.20 11.88 10.05 8.14 18.95 8.36 8.09 10.58 10.58 0.19 -0.27 0.67 -0.21 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-19.23 -19.21 -19.14 -14.58 -21.71 -22.75 -23.08 -18.14 -22.05 -18.54 -16.19 -12.15 -9.54 -6.23 13.70 18.31 15.81 12.55 28.36 12.05 11.85 14.26 14.67 -0.53 -0.20 -0.09 -0.24 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

3.4 3.2 3.5 3.5 3.5 3.5 4.2 4.5 4.4 4.7 4.4 4.4 4.6 4.5 5.2 5.0 5.1 4.2 4.1 4.5 5.3 6.2 6.6 5.8 5.8 5.8 5.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

329.0 874.0 431.1 - 719.7 356.8 1029.8 - - - - - - - - - - - - - 23.2 43.2 5.5 - - 3.7 8.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

329.0 - - - 719.7 356.8 1029.8 - - - - - - - - - - - - - 23.2 43.2 5.5 - - 3.7 8.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

329.0 - - - 719.7 356.8 1029.8 - - - - - - - - - - - - - 23.2 43.2 5.5 - - 3.7 8.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company AbCellera Biologics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
SIGA Technologies SIGA Technologies
SIGA
$ 2.4 -9.06 % $ 172 M usaUSA
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 7.56 0.4 % $ 351 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 28.3 0.68 % $ 1.32 B usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 55.64 2.88 % $ 155 M israelIsrael
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 8.71 -4.16 % $ 755 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 3.47 -6.48 % $ 371 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
$ 0.59 -4.42 % $ 36.2 M usaUSA
Jaguar Health Jaguar Health
JAGX
$ 0.24 -27.06 % $ 560 K usaUSA
Arvinas Arvinas
ARVN
$ 6.41 -4.9 % $ 454 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.86 -2.37 % $ 355 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 20.87 -0.36 % $ 2.06 B usaUSA
Inhibrx Inhibrx
INBX
$ 68.81 -7.43 % $ 3.24 B usaUSA
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 48.09 -4.54 % $ 5.52 B usaUSA
Revolution Medicines Revolution Medicines
RVMD
$ 161.01 0.99 % $ 30.6 B usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
$ 3.29 0.15 % $ 152 M israelIsrael
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
- - $ 459 M usaUSA
Legend Biotech Corporation Legend Biotech Corporation
LEGN
$ 15.21 -5.53 % $ 5.61 B usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 2.04 -0.73 % $ 281 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.67 2.9 % $ 1.81 M chinaChina
Krystal Biotech Krystal Biotech
KRYS
$ 308.83 -2.21 % $ 8.94 B usaUSA
Kura Oncology Kura Oncology
KURA
$ 6.91 -6.05 % $ 606 M usaUSA
Inhibikase Therapeutics Inhibikase Therapeutics
IKT
$ 1.31 0.38 % $ 129 M usaUSA
Protara Therapeutics Protara Therapeutics
TARA
$ 2.28 -5.21 % $ 97.7 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.25 -5.3 % $ 41.7 M usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
$ 1.76 2.63 % $ 82.5 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 9.66 -3.5 % $ 763 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.66 -0.37 % $ 32.8 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
- -5.76 % $ 99.8 M usaUSA
Innoviva Innoviva
INVA
$ 18.42 0.03 % $ 1.24 B usaUSA
BioCardia BioCardia
BCDA
$ 0.77 -0.08 % $ 5.13 M usaUSA
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.69 -0.01 % $ 11.3 B usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 1.52 -8.16 % $ 9.72 B australiaAustralia
Shineco, Inc. Shineco, Inc.
TYHT
- -3.90 % $ 97.2 M chinaChina
ORIC Pharmaceuticals ORIC Pharmaceuticals
ORIC
$ 7.34 -4.68 % $ 644 M usaUSA
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.
MLND
- -5.36 % $ 20.2 M usaUSA
Certara Certara
CERT
$ 10.56 -1.12 % $ 1.69 B usaUSA
Intec Pharma Ltd Intec Pharma Ltd
NTEC
- -12.45 % $ 17.7 M israelIsrael
Anika Therapeutics Anika Therapeutics
ANIK
$ 13.26 -0.15 % $ 190 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.23 -52.81 % $ 1.5 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.68 -4.63 % $ 171 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
$ 1.59 -5.92 % $ 2.08 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 63.61 -2.11 % $ 6.61 B usaUSA
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
Genprex Genprex
GNPX
$ 1.46 -12.87 % $ 1.36 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
$ 30.23 -7.1 % $ 510 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 0.87 -7.57 % $ 77.9 M franceFrance